Decreased Serum miR-1296 may Serve as an Early Biomarker for the Diagnosis of Non-Alcoholic Fatty Liver Disease.

BACKGROUND:Circulating microRNA has become a candidate biomarker for many diseases. The purpose of this study was to investigate the significance of miR-1296 as a non-invasive biomarker in nonalcoholic fatty liver disease (NAFLD). METHODS:Serum samples were collected from normal people and NAFLD patients for biochemical detection. Serum microRNAs were isolated by the NucleoZOL method, and the stem-loop method was used to reverse transcribe the DNA. The relative quantification of miR-1296 was performed by SYBR Green method. Spearman's method was used to analyze the correlation between miR-1296 and serum biochemical parameters. RESULTS:By using 2-∆∆CT method, we found that, compared with the normal control group, the expression of serum miR-1296 increased in patients with normal lipid NAFLD and those with hyperlipidemia NAFLD. At the same time, the expression of microRNA-1296 in the NAFLD hyperlipidemia group increased more significantly than that in the NFALD group with normal lipid. Spearman's correlation assay demonstrated that the correlation between the expression of miR-1296 and blood lipids, including TC, TG, HDL-c, and LDL-c, was TC (r = 0.4951, p = 0.0013), TG (r = 0.054, p = 0.6425), HDL-C (r = 0.3435, p = 0.07522), and LDL-C (r = 0.3307, p = 0.0699. The data showed that miR-1296 was positively correlated with serum TC level. CONCLUSIONS:In summary, serum microRNA-1296 is a more sensitive marker of NAFLD than blood lipids, which provides a new method for noninvasive early screening of NAFLD.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}